Vents came! A large number of medical equipment companies with foreign cooperation

Pharmaceutical Network Nov. 14 hearing The rapid growth of the medical device industry momentum, so that many businesses around the corner foreign brands want channels, local companies want products, the two sides hit it off, this year, there have been many cases of cooperation.

Dean Diagnostics announced on the evening of November 12 that it had signed a "joint venture agreement" with Shanghai Aibo Caosheng Analytical Instruments Trade Co., Ltd., a subsidiary of Danaher Corporation, one of the four giants in global in vitro diagnostics. Both parties intend to set up a joint venture in Hangzhou, China Jointly set up a joint venture company to develop, register, manufacture and market Class I, II and III in vitro diagnostic products and give full play to their respective advantages in order to achieve commercial success in the field of mass spectrum diagnosis in China.

The registered capital of the joint venture company is RMB 50 million, while DI Diagnostics owns 51% of the total shares and AIBC 49%. The joint venture will rely on the world's leading equipment and technology owned by Danaher in mass spectrometry testing Dean diagnosis in the country established a strong third-party medical testing platform service capabilities and sales network, to achieve the international advanced mass spectrometry detection technology in the country floor conversion.

Yesterday (November 13), China's largest home medical device vendor Rehabilitation House and MEDISANA, a German manufacturer of smart health products, announced the formation of Beijing Medicon Health Technology Co., Ltd.

It is reported that MEDISANA is a German company that combines health and medical device products. Founded in 1982 and headquartered in Düsseldorf, MEDISANA is a pioneer and leader in the field of home medical medical devices in Europe. Besides Germany, Britain, France, Russia , The United States, Australia, other Asian regions have also completed the layout.

On June 28, Guangdong Tianpeng Biochemical Pharmaceutical Co., Ltd., a critical disease enterprise, and Wako, a well-known diagnostic reagent manufacturer in Japan, jointly announced that they will reach a strategic cooperation to enter the field of Chinese in vitro diagnostic immunity The first project is the introduction of AFP / AFP-L3 / PIVKA II, the world's leading innovative liver cancer detection triple detection (hereinafter referred to as "triple detection"), through the technology to achieve rapid early diagnosis of hepatocellular carcinoma in 10 minutes The results of joint detection, the sensitivity and accuracy are very high, greatly improving the efficiency of early diagnosis and prognosis of liver cancer detection.

Wako, one of the world's leading suppliers of chemical reagents to laboratories, is a world-renowned manufacturer of reagents and reagents. Introducing Wako's innovative diagnostic products, not only is Th & P entering the field of in vitro diagnostics and creating a full range of solutions An important step, but also a powerful win-win cooperation between the two sides.

At the end of March, Beijing Bomai Medical signed a contract with the United States Kantor Group, and Bomai Medical authorized Condor's medical device company Contius to distribute the PTCA balloon catheter series under the Bomai medical brand in China.

As high-end medical equipment with high-tech, high value-added products, high-risk, Regulations Strict regulatory and other characteristics of high-end medical devices in the world have a high barriers to entry and barriers to the industry in the Chinese market, more than 80% of high-end high-value medical device products, has always been controlled by the international brands.

In the global high-end medical equipment market, basically difficult to see the Chinese-made brands.Bomai Medical in the field of cardiovascular intervention in high-end medical devices and Kantor reached a cooperation, reflecting its product strength, cardiovascular intervention is the world's largest medical device market segments .

In previous Sino-foreign cooperation, most of them were channels for the Chinese side to export their products, but this cooperation was the opposite. Multinational corporations became the exclusive national enterprises of local enterprises proxy Business

On January 10, Kehua Bio-Clinical Research announced that it signed a "strategic alliance and distribution agreement" with Biokit, confirming that the company fully represents Biokit SA's BioFlash desktop automated chemiluminescence immunoassay system , Including BioFlash instruments and their consumables and spare parts, as well as the sole agency for their infectious disease testing kits, marketing, sales and after-sales services, which is valid until the end of 2021.

Founded in 1973 and headquartered in Barcelona, ​​Spain, Biokit S.A. is an international developer and manufacturer of in vitro diagnostics and a subsidiary of the Wofen Group, a global leader in in vitro diagnostics.

In December last year, the United States of Great Health and Siemens to jointly set up and operate an independent medical imaging diagnostic center in Shanghai through this cooperation, Siemens Medical China through in-vitro diagnostic equipment and related data diagnostic services to improve the United States in health Screening, effectiveness of disease diagnosis, and efficiency and standardization of stores within the Midea Group.

Last October, Fosun medicine Announced that it intends to invest 40 million US dollars and Intuitive Surgical Intuitive a wholly owned subsidiary in Shanghai to set up a joint venture to develop, produce and sell products for the early diagnosis or treatment of lung cancer.

Last December, Fosun Pharma and the United States were intuitive medical instruments Company cooperation, the two sides will jointly inject 100 million US dollars to set up a joint venture in Shanghai enterprise , Which develops, manufactures and sells innovative products based on robotic-assisted catheter technology for the early diagnosis and treatment of lung cancer.

Last March, Neusoft Medical cooperated with Wittmann, Wittmann is an in vitro diagnostic reagent manufacturer in Japan and has been specializing in the research, production and sales of clinical biochemical diagnostic reagents since its establishment in 2001. Since 2009, Neusoft Medical Co., Ltd. A & T strategic cooperation in clinical testing equipment.